Gilead Sciences, Inc. Chases More Deals, Re-enters Cancer Medicines Market by Developing Combo Cancer Drugs

Gilead Sciences Inc. (GILD) is on a mission to make cancer more like AIDS -- an illness that can be kept at bay over the long term, rather than a lethal disease. The company, which leads the market for AIDS drugs, is re- entering the market for cancer medicines a decade after selling its oncology unit. Since December, Gilead has spent $600 million for two companies developing experimental therapies and signed a research deal with Yale University, just as scientists are suggesting that drug cocktails may work as well against cancer as they do against HIV.

Back to news